BETA

5 Amendments of Alberto CIRIO related to 2016/2057(INI)

Amendment 282 #
Motion for a resolution
Paragraph 10 a (new)
10a. Recognises that pricing and reimbursement of medicinal products are competences of Member States;
2016/10/21
Committee: ENVI
Amendment 349 #
Motion for a resolution
Paragraph 16
16. Highlights the possibility for a voluntary European procedure for joint procurement of medicines used for the acquisition of vaccineal countermeasures for serious cross border health threats in accordance with Decision No 1082/2013/EU;
2016/10/21
Committee: ENVI
Amendment 356 #
Motion for a resolution
Paragraph 16 a (new)
16a. Highlights the role of the European Union in monitoring and providing guidance on economic policies within the framework of the European Semester, and welcomes the production of country-specific recommendations in the field of healthcare sustainability;
2016/10/21
Committee: ENVI
Amendment 391 #
Motion for a resolution
Paragraph 19
19. Calls on the Commission to promote R&D driven by patients’ needs, while fostering social responsibility in the pharmaceutical sector, by setting up an EU public platform for R&D funded by contributions from profits made by the pharmaceutical industry through sales to public health systems; calls for transparency on the costs of R&D;deleted
2016/10/21
Committee: ENVI
Amendment 518 #
Motion for a resolution
Paragraph 27
27. Calls on the Council to increase coopesupport the exchange of good practionces between the Member States as regards price-setting procedures, in order to share information about prices, reimbursement, negotiation agreements and good practices and to avoid unnecessary administrative requirements and delayson those aspects where cooperation can lead to broader and faster patient access, while also preserving necessary incentives for innovation;
2016/10/21
Committee: ENVI